Current Portfolio
EQT invests in good companies with a mission to help them develop into great companies.
EQT invests in good companies with a mission to help them develop into great companies.
Company | Sector | Fund | Market | Entry |
|---|---|---|---|---|
| Aerska | Life Sciences | LSP Dementia Fund | Ireland | 2025 |
| Agomab Therapeutics | Life Sciences | LSP 7 | Belgium | 2023 |
| Am-Pharma | Life Sciences | LSP 6 | Netherlands | 2019 |
| Ariceum Therapeutics | Life Sciences | LSP 7 | Germany | 2021 |
| Artios Pharma | Life Sciences | LSP 6 | United Kingdom | 2018 |
| AstronauTx | Life Sciences | LSP Dementia Fund | United Kingdom | 2023 |
| Atalanta Therapeutics | Life Sciences | LSP Dementia Fund | United States | 2024 |
| ATB Therapeutics | Life Sciences | LSP 7 | Belgium | 2024 |
| Atlantic Therapeutics | Life Sciences | LSP HEF 2 | Ireland | 2018 |
| AviadoBio | Life Sciences | LSP Dementia Fund | United Kingdom | 2021 |
| Avidicure | Life Sciences | LSP 7 | Netherlands | 2024 |
| Binx Health | Life Sciences | LSP 4 | United Kingdom | 2021 |
| Binx Health | Life Sciences | LSP 6 | United Kingdom | 2021 |
| BioArctic | Life Sciences | LSP Dementia Fund | Sweden | 2025 |
| Cardiac Dimensions | Life Sciences | LSP HEF 1 | United States | 2015 |
| Cyted Health | Life Sciences | EQT HE 3 | United Kingdom | 2025 |
| DNA Script | Life Sciences | LSP 6 | France | 2019 |
| DOTS Technology | Life Sciences | LSP HEF 2 | United States | 2021 |
| Egle Therapeutics | Life Sciences | LSP 7 | France | 2021 |
| Electra Therapeutics | Life Sciences | LSP 7 | United States | 2025 |
| Eloxx Pharma | Life Sciences | LSP 5 | United States | 2017 |
| eTheRNA | Life Sciences | LSP 5 | Belgium | 2016 |
| Evommune | Life Sciences | LSP 7 | United States | 2021 |
| Exciva | Life Sciences | LSP Dementia Fund | Germany | 2025 |
| Eyesense | Life Sciences | LSP 3 | Switzerland | 2006 |